Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.78 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.76 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12643220 | 0.87 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL15481296 | 0.87 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL17527057 | 0.87 | CCR1 (0.97) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL12859074 | 0.86 | CCR1 (0.71) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL3647594 | 0.86 | NR4A2 (1.00) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL13608906 | 0.84 | CCR1 (0.68) | CCR1NR4A2FERMT2CYP1A2BACE1 | |
| SCHEMBL11757988 | 0.84 | CCR1 (0.86) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL19407562 | 0.84 | CCR1 (0.91) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL12871439 | 0.83 | CCR1 (0.67) | CCR1NR4A2FERMT2CYP1A2HRH3 | |
| SCHEMBL11756506 | 0.83 | CCR1 (0.84) | CCR1NR4A2FERMT2CYP1A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021202669-A2 | NUCLEOSIDE AND NUCLEOTIDE CONJUGATE COMPOUNDS AND USES THEREOF | REYOUNG CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |